alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › phosphorylation

phosphorylation

387 studies tagged phosphorylation, dated 1987-01-01 to 2026-10-31. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. APH-1A and CDK5 Expression Correlates with Tau Hyperphosphorylation and Its Attenuation by Brahmi and Donep-M in STZ induced Alzheimer’s Disease Model 2026-10-31
  2. Opposing Regulation of Tau Condensation by Phosphorylation Levels and Molecular Chaperone Interactions 2026-10-30
  3. The Alzheimer's disease-associated rs28834970 variant in PTK2B impairs electrical activity and regulates Tau phosphorylation and APP processing in human neuronal cultures 2026-10-30

Studies

387 studies carry this tag.

Date range

1987 to 2026

Top journals

  • Acta neuropathologica 16
  • Alzheimer's & dementia : the journal of the Alzheimer's Association 12
  • bioRxiv 12
  • Molecular neurodegeneration 10
  • Research Square 10

173 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. The journal of prevention of Alzheimer's disease 2019 Drug development

    Efforts to develop effective disease-modifying treatments for Alzheimer's disease (AD) have mostly targeted the amyloid β (Aβ) protein; however, there has recently been increased interest in other targets including phosphorylated tau and other forms of tau.

  2. Cerebrospinal Fluid and Plasma Tau as a Biomarker for Brain Tauopathy

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. Advances in experimental medicine and biology 2019 Tau biomarkers

    Cerebrospinal fluid (CSF) tau and phosphorylated tau (ptau) are definite biomarkers of Alzheimer's disease (AD).

  3. A simplified radiosynthesis of [18 F]MK-6240 for tau PET imaging

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of labelled compounds & radiopharmaceuticals 2018-12-19 Brain scans and imaging

    [18 F]MK-6240 (6-(fluoro)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine) is a highly selective PET radiotracer for the in vivo imaging of neurofibrillary tangles (NFTs). [18 F]MK-6240 was synthesized in one step from its bis-Boc protected precursor N-[(tert-butoxy)carbonyl]-N-(6-nitro-3-[1H-pyrrolo[2,3-c]pyridin-1-yl]isoquinolin-5-yl) carbamate in DMSO using [18 F] fluoride with TEA HCO3 with step-wise heating up to 150°C, resulting in an isolated radiochemical yield of 9.8% ± 1.8% (n = 3) calculated from the end of bombardment (5.2% ± 1.0% calculated from the end of synthesis).

  4. A tau homeostasis signature is linked with the cellular and regional vulnerability of excitatory neurons to tau pathology

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Nature neuroscience 2018-12-17 Genetics

    Excitatory neurons are preferentially impaired in early Alzheimer's disease but the pathways contributing to their relative vulnerability remain largely unknown.

  5. Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 64 out of 100. Acta neuropathologica 2018-12-13 Drug development

    Tau is an axonal microtubule-binding protein.

  6. Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Neuron 2018-11-01 Genetics

    Synapse loss and Tau pathology are hallmarks of Alzheimer's disease (AD) and other tauopathies, but how Tau pathology causes synapse loss is unclear.

  7. Imaging the evolution and pathophysiology of Alzheimer disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Nature reviews. Neuroscience 2018-11-01 Brain scans and imaging

    Technologies for imaging the pathophysiology of Alzheimer disease (AD) now permit studies of the relationships between the two major proteins deposited in this disease - amyloid-β (Aβ) and tau - and their effects on measures of neurodegeneration and cognition in humans.

  8. Cellular Prion Protein Mediates the Disruption of Hippocampal Synaptic Plasticity by Soluble Tau In Vivo

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. The Journal of neuroscience : the official journal of the Society for Neuroscience 2018-10-24 Drug development

    Intracellular neurofibrillary tangles (NFTs) composed of tau protein are a neuropathological hallmark of several neurodegenerative diseases, the most common of which is Alzheimer's disease (AD).

  9. Highly specific and selective anti-pS396-tau antibody C10.2 targets seeding-competent tau

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer's & dementia (New York, N. Y.) 2018-10-14 Drug development

    The antibody C10.2 bound specifically to pS396-tau with an IC50 of 104 pM and detected preferentially hyperphosphorylated tau aggregates from AD brain with an IC50 of 1.2 nM.

  10. Tau protein aggregation is associated with cellular senescence in the brain

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Aging cell 2018-10-11 Genetics

    Tau protein accumulation is the most common pathology among degenerative brain diseases, including Alzheimer's disease (AD), progressive supranuclear palsy (PSP), traumatic brain injury (TBI), and over twenty others.

  11. The Role of Tau Imaging in Parkinsonian Disorders

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Current neurology and neuroscience reports 2018-10-06 Drug development

    Differential diagnosis of atypical Parkinson syndromes (APS) is difficult as clinical presentations may vary and as there is a strong overlap between disease entities.

  12. Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Acta neuropathologica 2018-09-20 Drug development

    In Alzheimer's disease (AD) and other tauopathies, the cytosolic protein Tau misfolds and forms intracellular aggregates which accumulate within the brain leading to neurodegeneration.

  13. Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Acta neuropathologica communications 2018-08-22 Drug development

    Tau, the main component of the neurofibrillary tangles (NFTs), is an attractive target for immunotherapy in Alzheimer's disease (AD) and other tauopathies.

  14. The development and validation of tau PET tracers: current status and future directions

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Clinical and translational imaging 2018-07-20 Brain scans and imaging

    Tau PET tracers have enabled in vivo quantification of PHF-tau burden in human brains.

  15. A novel electrochemical aptamer-antibody sandwich assay for the detection of tau-381 in human serum

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. The Analyst 2018-07-01 Drug development

    Tau protein plays a crucial role in the pathogenesis of Alzheimer's disease (AD).

  16. Tau-targeting therapies for Alzheimer disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Nature reviews. Neurology 2018-07-01 Drug development

    Alzheimer disease (AD) is the most common form of dementia.

  17. Acute tau knockdown in the hippocampus of adult mice causes learning and memory deficits

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Aging cell 2018-05-10 Drug development

    Misfolded and hyperphosphorylated tau accumulates in several neurodegenerative disorders including Alzheimer's disease, frontotemporal dementia with Parkinsonism, corticobasal degeneration, progressive supranuclear palsy, Down syndrome, and Pick's disease.

  18. Extracellular Monomeric and Aggregated Tau Efficiently Enter Human Neurons through Overlapping but Distinct Pathways

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Cell reports 2018-03-01 Drug development

    In Alzheimer's disease, neurofibrillary tangle pathology appears to spread along neuronal connections, proposed to be mediated by the release and uptake of abnormal, disease-specific forms of microtubule-binding protein tau MAPT.

  19. Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2018-02-23 Brain scans and imaging

    Ligands targeting tau for use with positron emission tomography have rapidly been developed during the past several years, enabling the in vivo study of tau pathology in patients with Alzheimer's disease and related non-Alzheimer's disease tauopathies.

  20. Tau-Targeted Multifunctional Nanocomposite for Combinational Therapy of Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. ACS nano 2018-02-01 Drug development

    Alzheimer's disease (AD) remains an incurable disease and lacks efficient diagnostic methods.

  21. Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer's research & therapy 2018-01-31 Drug development

    These findings indicate that AD p-Tau-injected 3 × Tg-AD mice represent a practical model to study the seeding and spread of Tau pathology, their effect on Aβ pathology, and the effect of Tau immunotherapy on both Tau and Aβ pathologies.

  22. Assay of Plasma Phosphorylated Tau Protein (Threonine 181) and Total Tau Protein in Early-Stage Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of Alzheimer's disease : JAD 2018-01-01 Biomarkers

    The feasibility of assaying plasma phosphorylated tau protein (threonine 181), denoted p-tau181, using immunomagnetic reduction (IMR) is explored.

  23. The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Movement disorders : official journal of the Movement Disorder Society 2017-12-26 Brain scans and imaging

    High affinity of AV-1451 for monoamine oxidase proteins may limit its utility as a tau PET tracer in PSP and Alzheimer's disease because of high levels of monoamine oxidase expression in brain regions also affected by tau deposition, especially if monoamine oxidase levels change over time or with a treatment intervention. © 2017 International Parkinson and Movement Disorder Society.

  24. Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Chinese medical journal 2017-12-20 Drug development

    Amyloid plaques enriched with extracellular amyloid beta (Aβ) and intracellular neurofibrillary tangles comprised of hyperphosphorylated tau proteins are the two main pathological hallmarks of AD.

  25. "Tau immunotherapy: Hopes and hindrances"

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Human vaccines & immunotherapeutics 2017-12-01 Drug development

    Alzheimer's disease (AD) is a progressive neurological disorder having two major pathological hallmarks: the extracellular senile plaques and intracellular neurofibrillary tangles composed of amyloid beta protein and hyperphosphorylated tau respectively.

  26. Cis P-tau is induced in clinical and preclinical brain injury and contributes to post-injury sequelae

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Nature communications 2017-10-17 Drug development

    Traumatic brain injury (TBI) is characterized by acute neurological dysfunction and associated with the development of chronic traumatic encephalopathy (CTE) and Alzheimer's disease.

  27. Tauopathy and cognitive impairment in experimental diabetes mellitus

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Diabetes mellitus 2017-08-10 Risk factors

    Currently, diabetes mellitus (DM) is the most common metabolic disorder, which is manifested by hyperglycemia and leads to vascular and cognitive impairment.

  28. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. The Lancet. Neurology 2017-06-13 Getting a diagnosis

    Progressive supranuclear palsy (PSP), previously believed to be a common cause of atypical parkinsonism, is now recognised as a range of motor and behavioural syndromes that are associated with a characteristic 4-repeat tau neuropathology.

  29. YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer’s disease and other tauopathies

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of Neuroinflammation 2017-06-09 Biomarkers

    We found that brain YKL-40 immunoreactivity was observed in a subset of astrocytes in all four diseases and in controls.

  30. Anti-tau vaccine is successful in clinical trial for people with Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Nursing older people 2017-05-31 Drug development

    Alzheimer's disease progressively impairs cognition and daily function, and death usually occurs five to ten years after diagnosis.

  31. Emerging amyloid and tau targeting treatments for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Expert review of neurotherapeutics 2017-05-19 Drug development

    With an ageing global population, the number of people with dementia, and its main cause Alzheimer's disease (AD), is growing. current licensed treatments available for ad are only alleviate the symptoms of the disease, and are effective only in some people with ad for a limited time. there are currently no therapies that target the disease process.

  32. Phosphorylation of tau at Y18, but not tau-fyn binding, is required for tau to modulate NMDA receptor-dependent excitotoxicity in primary neuronal culture

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Molecular neurodegeneration 2017-05-19 Drug development

    Although tau has been implicated in diverse neurological diseases, its most pathogenic forms remain to be defined.

  33. Tau at the Crossroads between Neurotoxicity and Neuroprotection

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Neuron 2017-05-17 Drug development

    In contrast to the idea that tau phosphorylation is toxic, Ittner et al. (2016) recently showed that specific tau phosphorylation is neuroprotective, phenocopying tau ablation (DeVos et al., 2017), thus highlighting the complex tau biology that underlies neurotoxicity and neuroprotection.

  34. Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Brain : a journal of neurology 2017-05-01 Drug development

    Alzheimer's disease is characterized by the deposition of amyloid-β as extracellular plaques and hyperphosphorylated tau as intracellular neurofibrillary tangles.

  35. Tau Positron Emission Tomography Imaging

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Cold Spring Harbor perspectives in biology 2017-05-01 Brain scans and imaging

    Alzheimer's disease (AD) is a chronic neurodegenerative disorder and the most common cause of dementia among the elderly population.

  36. Liraglutide Improves Water Maze Learning and Memory Performance While Reduces Hyperphosphorylation of Tau and Neurofilaments in APP/PS1/Tau Triple Transgenic Mice

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Neurochemical research 2017-04-06 Drug development

    The purpose of this study was to explore how liraglutide affects AD-like pathology and cognitive function in APP/PS1/Tau triple transgenic (3 × Tg) Alzheimer disease (AD) model mice.

  37. Roles of tau protein in health and disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Acta neuropathologica 2017-04-06 Disease mechanisms

    Tau is well established as a microtubule-associated protein in neurons.

  38. Altered Synapse Stability in the Early Stages of Tauopathy

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Cell reports 2017-03-28 Disease mechanisms

    Synapse loss is a key feature of dementia, but it is unclear whether synaptic dysfunction precedes degenerative phases of the disease.

  39. A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Scientific reports 2017-03-13 Drug development

    Tau acetylation has recently emerged as a dominant post-translational modification (PTM) in Alzheimer's disease (AD) and related tauopathies.

  40. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Brain : a journal of neurology 2017-03-01 Brain scans and imaging

    Diverse neurodegenerative disorders are characterized by deposition of tau fibrils composed of conformers (i.e. strains) unique to each illness.

  41. Photobiomodulation with Near Infrared Light Helmet in a Pilot, Placebo Controlled Clinical Trial in Dementia Patients Testing Memory and Cognition

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of neurology and neuroscience 2017-02-28 Treatments

    Alzheimer's disease (AD) is a common, chronic expensive debilitating neurodegenerative disease with no current treatments to prevent the physical deterioration of the brain and the consequent cognitive deficits.

  42. Tau PET imaging: present and future directions

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Molecular neurodegeneration 2017-02-20 Brain scans and imaging

    Abnormal aggregation of tau in the brain is a major contributing factor in various neurodegenerative diseases.

  43. Tau passive immunization inhibits not only tau but also Aβ pathology

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer's research & therapy 2017-01-10 Drug development

    These findings suggest the potential of passive immunization targeting proximal N-terminal domain tau 6-18 as a disease-modifying approach to AD and related tauopathies.

  44. Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Proceedings of the National Academy of Sciences of the United States of America 2017-01-03 Drug development

    Alzheimer's disease (AD) and other neurodegenerative disorders are associated with the cytoplasmic aggregation of microtubule-associated protein tau.

  45. Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of Alzheimer's disease : JAD 2017-01-01 Disease mechanisms

    Amyloid-beta (Aβ) and hyperphosphorylated tau are hallmark lesions of Alzheimer's disease (AD).

  46. Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. The journal of prevention of Alzheimer's disease 2017-01-01 Drug development

    Tau neurofibrillary tangles are found in the brains of patients suffering from Alzheimer's disease and other tauopathies.

  47. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

    ✓ Peer-reviewed alzhub usefulness score 78 out of 100. The Lancet. Neurology 2016-12-10 Caregiving

    We randomly assigned patients with a computer-generated sequence in a 4:1 ratio overall to receive AADvac1 or placebo.

  48. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

    ✓ Peer-reviewed alzhub usefulness score 79 out of 100. Lancet (London, England) 2016-11-16 Drug development

    The prespecified primary analyses did not show any treatment benefit at either of the doses tested for the coprimary outcomes (change in ADAS-Cog score compared with control [n=354, 6·32, 95% CI 5·31-7·34]: 75 mg LMTM twice a day [n=257] -0·02, -1·60 to 1·56, p=0·9834, 125 mg LMTM twice a day [n=250] -0·43, -2·06 to 1·20, p=0·9323; change in ADCS-ADL score compared with control [-8·22, 95% CI -9·63 to -6·82]: 75 mg LMTM twice a day -0·93, -3·12 to 1·26, p=0·8659; 125 mg LMTM twice a day -0·34, -2·61 to 1·93, p=0·9479).

  49. Tau and tauopathies

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Brain research bulletin 2016-09-09 Disease mechanisms

    Most neurodegenerative diseases are characterized by intracellular aggregates of insoluble proteins.

  50. Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Cell reports 2016-07-28 Drug development

    The spread of tau pathology correlates with cognitive decline in Alzheimer's disease.

From across this tag

9 of the 387 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.

All topic tags with their study counts